Optimal therapy in Gaucher disease

References

• Goker-AlpanOSchiffmannRParkJKStubblefieldBKTayebiNSidranskyEPhenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3J Pediatr200314327327612970647
   PubMed Web of Science ®Google Scholar
• BarneveldRAKeijzerWTegelaersFPAssignment of the gene coding for human beta-glucocerebrosidase to the region q21–q31 of chromosome 1 using monoclonal antibodiesHum Genet1893642272316885065
   PubMedGoogle Scholar
• HruskaKSLaMarcaMEScottCRSidranskyEGaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)Hum Mutat20082956758318338393
   PubMed Web of Science ®Google Scholar
• Goker-AlpanOHruskaKSOrviskyEDivergent phenotypes in Gaucher disease implicate the role of modifiersJ Med Genet200542e3715937077
   PubMed Web of Science ®Google Scholar
• LachmannRHGrantIRHalsallDCoxTMTwin pairs showing discordance of phenotype in adult Gaucher’s diseaseQJM20049719920415028849
   PubMed Web of Science ®Google Scholar
• HruskaKSLaMarcaMESidranskyEGaucher DiseaseFutermanAHZimranABoca Raton, FLCRC Press20061348
   Google Scholar
• BeutlerEGrabowskiGAScriverCRBeaudetALValleDSlyWSThe Metabolic and Molecular Bases of Inherited DiseasesNew York, NYMcGraw-Hill2001
   Google Scholar
• ConradiNGKalimoHSouranderPReactions of vessel walls and brain parenchyma to the accumulation of Gaucher cells in the Norrbottnian type (type III) of Gaucher diseaseActa Neuropathologica2004753853903364161
   PubMedGoogle Scholar
• WenstrupRJRoca-EspiauMWeinrebNJBembiBSkeletal aspects of Gaucher disease: a reviewBr J Radiol200275Suppl 1A2A1212036828
   PubMed Web of Science ®Google Scholar
• GoiteinOElsteinDAbrahamovALung involvement and enzyme replacement therapy in Gaucher’s diseaseQ J Med200194407415
   Google Scholar
• KaplanPAnderssonHCKacenaKAYeeJDThe clinical and demographic characteristics of non-neuronopathic Gaucher disease in 887 children at diagnosisArch Pediatr Adolesc Med200616060360816754822
   PubMed Web of Science ®Google Scholar
• GinnsEIChoudaryPVTsujiSGene mapping and leader polypeptide sequence of human glucocerebrosidase: implications for Gaucher diseaseProc Natl Acad Sci U S A198582710171053863141
   PubMed Web of Science ®Google Scholar
• Berg-FussmanAGraceMEIoannouYGrabowskiGAHuman acid beta-glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activityJ Biol Chem199326814861148668325864
   PubMed Web of Science ®Google Scholar
• GrabowskiGAGattHorowitzMAcid β-glucosidase: enzymology and molecular biology of Gaucher diseaseCrit Rev Biochem Mol Biol1990253854142127241
   PubMed Web of Science ®Google Scholar
• VaccaroAMTattiMCiaffoniFSalvioliRBarcaAScerchCEffect of saposins A and C on the enzymatic hydrolysis of liposomal glucosylceramideJ Biol Chem199027216862168679201993
   PubMedGoogle Scholar
• MorimotoSKishimotoYTomichJInteraction of Saposins, Acid Lipids, and GlucosylceramidaseJ Biol Chem1990265193319372298731
   PubMed Web of Science ®Google Scholar
• PremkumarLSawkarARBoldin-AdamskySX-ray structure of human acid beta-glucosidase covalently bound to conduritol-β-epoxide. Implications for Gaucher diseaseJ Biol Chem2005280238152381915817452
   PubMed Web of Science ®Google Scholar
• DvirHHarelMMcCarthyAAX-ray structure of human acid β-glucosidase, the defective enzyme in Gaucher diseaseEMBO Rep2003200370470912792654
   PubMedGoogle Scholar
• GraceMEGravesPNSmithFIGrabowskiGAAnalysis of catalytic and inhibitor binding of human acid beta-glucosidase by site directed mutagenesisJ Biol Chem199425668276835
   Google Scholar
• SalvioloiRTattiMScarpaSThe N370S (Asn370Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin CBiochem J20053909510315826241
   PubMed Web of Science ®Google Scholar
• De DuveCFrom cytases to hydrolasesFederation Proceedings1964231045104914209796
   PubMedGoogle Scholar
• FrantoniJCHallCWNeufeldEFHurler and Hunter syndromes: mutual correction of the defect in cultured fibroblastsScience19681624685725693201
   PubMed Web of Science ®Google Scholar
• BradyROPentchevPGGalAEHibbertSRDekabanASReplacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher’s diseaseN Engl J Med19742919899934415565
   PubMed Web of Science ®Google Scholar
• FurbishFSSteetCJBarrangerJAJonesEABradyROThe uptake of naive and desialylated glucocerebrosidase by rate hepatocytes and Kupffer cellsBiochem Biophys Res Commun19788110471053666784
   PubMed Web of Science ®Google Scholar
• BeutlerEKuhlWVaughanLMFailure of alglucerase infused into Gaucher disease patients to localize in marrow macrophagesMol Med199513203248529110
   PubMed Web of Science ®Google Scholar
• DoebberTWWuMSBugianesiRLEnhanced macrophage uptake of synthetically glycosylated human placental β-glucocerebrosidaseJ Biol Chem1982252219321997061417
   PubMedGoogle Scholar
• SatoYBeutlerEBinding, internalization and degradation of mannose terminated glucocerebrosidase by macrophagesJ Clin Invest199391190919178486762
   PubMed Web of Science ®Google Scholar
• BartonNWBradyRODambrosiaJMReplacement therapy for inherited enzyme deficiency-macrophage targeted glucocerebroidase for Gaucher’s diseaseN Engl J Med1991234146414702023606
   PubMedGoogle Scholar
• XuYHPonceESunYLeonovaTBoveKWitteDGrabowskiGATurnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissuesPediatr Res1996393133228825806
   PubMed Web of Science ®Google Scholar
• MistryPKWraightEPCoxTMTherapeutic delivery of proteins to macrophages:Implications for treatment of Gaucher’s diseaseLancet1996348155515598950883
   PubMed Web of Science ®Google Scholar
• GrabowskiGAKacenaKColeJADose response relationships for enzyme replacement therapy with imiglucerase/aglucerase in patients with Gaucher disease type 1Genet Med2009119210019265748
   PubMed Web of Science ®Google Scholar
• AltarescuGSchiffmannRParkerCCComparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher diseaseBlood Cells Mol Dis20002628529011042029
   PubMed Web of Science ®Google Scholar
• FigueroaMLRosenbloomBEKayACA less costly regimen of aglucerase to treat Gaucher’s diseaseN Engl J Med1992327163216361435900
   PubMed Web of Science ®Google Scholar
• ZimranAHadas-HalpernIZevinSLevy-LahadEAbrahamovALow-dose high-frequency enzyme replacement therapy for very young children with severe Gaucher diseaseBr J Haematol1993857837867918044
   PubMed Web of Science ®Google Scholar
• WilsonCSpearingRTeagueLRobertsonPBlacklockHThe outcome of clinical parameters in adults with severe Type I Gaucher disease using very low dose enzyme replacement therapyMol Genet Metab20079213113617604204
   PubMed Web of Science ®Google Scholar
• de FostMAertsJGroenerJEMLow frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trialHaematologica20079221522117296571
   PubMed Web of Science ®Google Scholar
• KishnaniPSDiRoccoMKaplanPA randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in maintenance therapy of adult patients with Gaucher disease type 1Mol Genet Metab20099616417019195916
   PubMed Web of Science ®Google Scholar
• PastoresGMWeinrebNJAertsGSemin Hematol200441Suppl 541415468045
   PubMedGoogle Scholar
• DweckAAbrahamovAHadas-HalpernIBdolach-AvramTZimranAElsteinDType I Gaucher disease in children with and without enzyme therapyPediatr Hematol Onco20026389397
   Google Scholar
• AnderssonHKaplanPKacenaKYeeJEight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease Type 1Pediatrics20081221182119019047232
   PubMed Web of Science ®Google Scholar
• CharrowJAnderssonHCKaplanPEnzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendationsJ Pediatr200414411212014722528
   PubMed Web of Science ®Google Scholar
• GrabowskiGAAndriaGBaldellouAPediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statementsEur J Pediatr2004163586614677061
   PubMed Web of Science ®Google Scholar
• Brunel-GuittonCRivardGEGalipeauJEnzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage?Mol Gen Metab2009967376
   PubMed Web of Science ®Google Scholar
• BaldellouAAndriaGCampbellPEPaediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoringEur J Pediatr2004163677514677062
   PubMed Web of Science ®Google Scholar
• de FostMvan NoeselCJMJohannesMFGPersistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapyHematologica2008931191120
   Web of Science ®Google Scholar
• MistryPKSirrsSChanAPulmonary hypertension in type 1 Gaucher’s disease: genetic and epigenetic determinants of phenotype and response to therapyMol Genet Metab200277919812359135
   PubMed Web of Science ®Google Scholar
• CampbellPEHarrisCMVellodiADeterioration of the auditory brainstem response in children with type 3 Gaucher diseaseNeurology20046338538715277647
   PubMed Web of Science ®Google Scholar
• VellodiATylki-SzymanskaADaviesEHManagement of neuronopathic Gaucher disease: revised recommendationsJ Inherit Metab Dis20093266066419655269
   PubMed Web of Science ®Google Scholar
• SchiffmannRHeyesMPAertsJMProspective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher’s diseaseAnn Neurol1997426136219382473
   PubMed Web of Science ®Google Scholar
• BrumshteinBSalinasPPetersonBCharacterization of gene-activated human acid-β-glucosidase:crystal structure, glycan composition and internalization into macrophagesGlycobiology201020243219741058
   PubMed Web of Science ®Google Scholar
• ShaaltielYBartfeldDHashmueliSProduction of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell systemPlant Biotechnol J2007557959017524049
   PubMed Web of Science ®Google Scholar
• ZimranALovedayKFratazziCElsteinDA pharmacokinetic analysis of a novel enzyme replacement therapy with gene-activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher diseaseBlood Cells Mol Dis20073911511817391996
   PubMed Web of Science ®Google Scholar
• ScottMvan PattenSMHughesHEffect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher diseaseGlycobiology20071746747817251309
   PubMed Web of Science ®Google Scholar
• AviezerDBrill-AlmonEYoseph ShaaltielYPlant-derived recombinant human glucocerebrosidase enzyme – a preclinical and phase I investigationPLoS ONE20094e479219277123
   PubMed Web of Science ®Google Scholar
• PenneliNScaravilliFZacchelloFMorphogenesis of Gaucher cells investigated by electron microscopyBlood1969343313475804023
   PubMed Web of Science ®Google Scholar
• NillsonOHakanssonGDreborgSGrothCGSvernerholmLIncreased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type IIIClin Gene198222274279
   PubMed Web of Science ®Google Scholar
• CoxTLachmannRHollakCMNovel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycine (OGT 918) to decrease substrate biosynthesisLancet20003551481148510801168
   PubMed Web of Science ®Google Scholar
• HollakCEMHughesDvan SchaikIVSchwierinBBembiBMiglustat (Zavesca®) in type 1 Gaucher disease: 5-year results of a post-authorization safetyPharmacoepidem Dr S200918770777
   PubMed Web of Science ®Google Scholar
• PlattFMNeisesGRReikenmeiserGPrevention of lysosomal storage disease in Tay Sachs mice treated with N-butyldeoxynojirimycinScience19972764284319103204
   PubMed Web of Science ®Google Scholar
• ShiffmannRFitzGibbonEJHarrisCRandomized, controlled trial of miglustat in Gaucher’s disease Type 3Ann Neurol20086451452219067373
   PubMed Web of Science ®Google Scholar
• FutermanAHHannunYAThe complex life of simple sphingolipidsEMBO Rep2004577778215289826
   PubMed Web of Science ®Google Scholar
• ThompsonABarrowCJProtein conformational misfolding and amyloid formation: characteristics of a new class of disorders that include Alzheimer’s and prion diseasesCurr Med Chem200291751176212369885
   PubMed Web of Science ®Google Scholar
• GregersenNProtein misfolding disorders: pathogenesis and interventionJ Inherit Metab Dis20062945647016763918
   PubMed Web of Science ®Google Scholar
• ChitiFDobsonCMProtein misfolding, functional amyloid, and human diseaseAnnu Rev Biochem20067533336616756495
   PubMed Web of Science ®Google Scholar
• LwinAOrviskyEGoker-AlpanOLaMarcaMESidranskyEGlucocerebrosidase mutations in subjects with parkinsonismMol Genet Metab200481707314728994
   PubMed Web of Science ®Google Scholar
• Goker-AlpanOSchiffmannRLaMarcaMENussbaumRLMcInerney-LeoASidranskyEParkinsonism among Gaucher disease carriersJ Med Genet20044193794015591280
   PubMed Web of Science ®Google Scholar
• Goker-AlpanOGiassonBIEblanMJGlucocerebrosidase mutations are an important risk factor for Lewy body disordersNeurology20066790891016790605
   PubMed Web of Science ®Google Scholar
• FanJQA contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activityTrends Pharmacol Sci20032435536012871668
   PubMed Web of Science ®Google Scholar
• ButtersTDPharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disordersExpert Opin Pharmacother2007842743517309337
   PubMed Web of Science ®Google Scholar
• SawkarARChengWCBeutlerEWongCHBalchWEKellyJWChemical chaperones increase the cellular activity of N370S β-glucosidase: a therapeutic strategy for Gaucher diseaseProc Natl Acad Sci U S A200299154283154312434014
   PubMed Web of Science ®Google Scholar
• ChangHHAsanoNIshiiSIchikawaYFanJQHydrophilic imino sugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patientsFEBS J20062734082409216934036
   PubMed Web of Science ®Google Scholar
• SteetRAChungSWustmanBPoweADoHKornfeldSAThe imino sugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanismsProc Natl Acad Sci U S A2006103138131381816945909
   PubMed Web of Science ®Google Scholar
• SawkarARAdamski-WernerSLChengWCGaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profilesChem Biol2005121235124416298303
   PubMed Web of Science ®Google Scholar
• StanleyPSundaramSTangJShiSMolecular analysis of three gain-of-function CHO mutants that add the bisecting GlcNAc to N-glycansGlycobiology200515435315329358
   PubMed Web of Science ®Google Scholar
• KhannaRBenjaminERPellegrinoLThe pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidaseFEBS J201027771618163820148966
   PubMed Web of Science ®Google Scholar
• SteetRChungSLeeWSPineCWDoHKornfeldSSelective action of the imino sugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidaseBiochem Pharmacol2007731376138317217920
   PubMed Web of Science ®Google Scholar
• MuTWFowlerDMKellyJWPartial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasisPLoS Biol20086e2618254660
   PubMed Web of Science ®Google Scholar
• RigatBMahuranDDiltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cellsMol Genet Metab20099622523219167257
   PubMed Web of Science ®Google Scholar
• SunYLiouBQuinnBRanHXuYHGrabowskiGAIn vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse modelsPLoS One20094e732019809509
   PubMed Web of Science ®Google Scholar
• ZhengWPadiaJUrbanDJThree classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher diseasePNAS2007104131921319717670938
   PubMed Web of Science ®Google Scholar
• MaegawaGHTropakMBButtnerJDIdentification and characterization of ambroxol as an enzyme enhancement agent for Gaucher diseaseJ Biol Chem2009284235022351619578116
   PubMed Web of Science ®Google Scholar
• MollerHJDeFostMAertsHHollakCMoestrupSKPlasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher’s diseaseEur J Haematol20047213513914962251
   PubMed Web of Science ®Google Scholar
• BovenLAvan MeursMBootRGGaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophagesAm J Clin Pathol200412235936915362365
   PubMed Web of Science ®Google Scholar
• DouglasBRobinsonRHGlewATartrate-resistant acid phosphatase from gaucher spleenJ Biol Chem1980255586458707380839
   PubMed Web of Science ®Google Scholar
• SilversteinEPertschukLPFriedlandJImmunofluorescent detection of angiotensin-converting enzyme (ACE) in Gaucher cellsAm J Med1980694084106251722
   PubMed Web of Science ®Google Scholar
• HollakCEMMaasMAertsJMClinically relevant therapeutic endpoints in type I Gaucher diseaseJ Inherit Metab Dis200124Suppl 29710511758685
   PubMedGoogle Scholar
• HollakCEvan WeelySvan OersMHAertsJMMarked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher diseaseJ Clin Invest199493128812928132768
   PubMed Web of Science ®Google Scholar
• BootRGVerhoekMLangeveldMCCL18: a urinary marker of Gaucher cell burden in Gaucher patientsJ Inherit Metab Dis200629456457116736095
   PubMed Web of Science ®Google Scholar
• AertsJMvan BreemenMJBussinkAPBiomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher diseaseActa Paediatr200897714
   PubMed Web of Science ®Google Scholar
• MoranMTSchofieldJPHaymanARShiGPYoungECoxTMPathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin KBlood2000961969197810961902
   PubMed Web of Science ®Google Scholar
• RogowskiOShapiraIZimranAAutomated system to detect low-grade underlying inflammatory profile: Gaucher disease as a modelBlood Cells Mol Dis200534262915607696
   PubMed Web of Science ®Google Scholar
• HermanSKrönkeGSchettGMolecular mechanisms of inflammatory bone damage, emerging trends for therapyTrends Mol Med200814624525318468489
   PubMed Web of Science ®Google Scholar
• BargagliEMargollicciMNikiforakisNChitotriosidase activity in the serum of patients with sarcoidosis and pulmonary tuberculosisRespiration20077454855217347558
   PubMed Web of Science ®Google Scholar
• BootRGHollakCEVerhoekMAlbertsCJonkersREAertsJMPlasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosisClin Chim Acta2010411313619808030
   PubMed Web of Science ®Google Scholar
• BargagliEMaggiorelliCRottoliPChitotriosidase in patients with interstitial lung diseaseRespiration20087623423818487875
   PubMed Web of Science ®Google Scholar
• Goker-AlpanOGiassonBIEblanMJGlucocerebrosidase mutations are an important risk factor for Lewy body disordersNeurology20066790891016790605
   PubMed Web of Science ®Google Scholar
• Goker-AlpanOLopezGVithayathlJDavisJHallettMSidranskyEThe spectrum of parkinsonian manifestations associated with glucocerebrosidase mutationsArch Neurol2008651353135718852351
   PubMed Web of Science ®Google Scholar
• Gan-OrZGiladiNRozovskiUGenotype-phenotype correlations between GBA mutations and Parkinson disease risk and onsetNeurology2008702277228318434642
   PubMed Web of Science ®Google Scholar